Exelixis: CABINET Subgroup Data Reinforce NET Adoption, But Thesis Unchanged

What happened

Exelixis reported a subgroup analysis from the Phase 3 CABINET trial at ASCO 2026, showing CABOMETYX significantly improved progression-free survival versus placebo in advanced neuroendocrine tumors regardless of functional status. This data bolsters the NET label expansion that drove Exelixis's 2025 guidance and supports continued adoption in a market where CABOMETYX has already captured ~35% new-patient share in 2L+ oral therapies. However, the news is incremental rather than transformative, as the CABINET primary results were already positive and the NET opportunity is fully embedded in management's 2026 revenue guidance of $2.325–2.425B. The DeepValue report rates the stock a WAIT at ~$44, citing a well-owned momentum name where zanzalintinib's optionality is increasingly capitalized but key structural threats—policy pricing and a 2026–2033 patent cliff—sit just outside the 6–18 month window. The stock trades at ~17x EPS with limited margin of safety, and the data does not alter the base-case scenario of 55% probability and $48 implied value.

Implication

The CABINET subgroup analysis provides incremental evidence that CABOMETYX is effective across NET subtypes, reinforcing the commercial momentum that underpins Exelixis's 2026 guidance and near-term cash flows. However, the stock's 50–60% run over the past year already reflects this NET expansion, and the core thesis issues—single-product concentration, patent vulnerability, and policy headwinds—remain unresolved. At ~17x EPS and with the stock near the attractive entry level of $38, the risk/reward is balanced but not compelling for new longs without a pullback or a clear catalyst from zanzalintinib. Investors should continue to monitor Cabometyx market share trends and the zanzalintinib NDA status; the data does not justify upgrading from WAIT to BUY.

Thesis delta

The subgroup data validates the NET opportunity already priced into the stock, so there is no fundamental shift in the investment thesis. The core narrative remains unchanged: Exelixis is a high-quality oncology cash-flow compounder with a strong balance sheet, but limited upside from current levels given the crowded positioning and upcoming patent cliff. The thesis continues to hinge on whether Cabometyx can sustain growth above guidance and whether zanzalintinib achieves regulatory success—neither of which is de-risked by this news.